6,7,4'-Trihydroxyisoflavone

6,7,4’-Trihydroxyisoflavone is an active metabolite of the phytoestrogen daidzein (Item No. 10005166).^1,2,3,4 It suppresses anchorage-dependent and -independent growth of HCT116 and DLD-1 colon cancer cells, as well as induces cell cycle arrest at the S and G₂/M phases in HCT116 cells when used at concentrations ranging from 12.5 to 100 µM.¹ 6,7,4'-Trihydroxyisoflavone (40 and 80 µM) inhibits adipogenesis in 3T3-L1 preadipocytes induced by isobutylmethylxanthine, dexamethasone, and insulin (MDI).² In vivo, 6,7,4'-trihydroxyisoflavone (5 mg/kg) reverses scopolamine-induced memory impairments and increases hippocampal brain-derived neurotrophic factor (BDNF) and CREB levels in mice.³ It also prevents LPS-induced bone loss in mice.⁴

WARNING This product is not for human or veterinary use.

1. Lee, D.E., Lee, K.W., Jung, S.K., et al. 6,7,4'-Trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2. Carcinogenesis 32(4), 629-635 (2011).

2. Seo, S.G., Yang, H., Shin, S.H., et al. A metabolite of daidzein, 6,7,4'-trihydroxyisoflavone, suppresses adipogenesis in 3T3-L1 preadipocytes via ATP-competitive inhibition of PI3K. Mol. Nutr. Food Res. 57(8), 1446-1455 (2013).

3. Ko, Y.-H., Kim, S.Y., Lee, S.-Y., et al. 6,7,4'-Trihydroxyisoflavone, a major metabolite of daidzein, improves learning and memory via the cholinergic system and the p-CREB/BDNF signaling pathway in mice. Eur. J. Pharmacol. 826, 140-147 (2018).

4. Kim, E.-N., Kim, Y.G., Lee, J.-H., et al. 6,7,4'-Trihydroxyflavone inhibits osteoclast formation and bone resorption in vitro and in vivo. Phytother. Res. 33(11), 2948-2959 (2019).